To evaluate the efficacy and safety of venetoclax, chidamide, and chiglitazar sodium (VCC) in patients with relapsed or refractory acute myeloid leukemia (R/R AML).
Refractory AML, defined as failure to achieve remission after at least one prior treatment;
Relapsed AML, defined as ≥5% blasts in the bone marrow after a previous remission;
AML arising from myelodysplastic syndrome (including CMML) or myeloproliferative neoplasms (secondary AML or therapy-related AML [t-AML]) is also eligible.
Age ≥18 years, regardless of sex, with an expected survival of >3 months.
Acute promyelocytic leukemia (APL).
Active central nervous system leukemia.
Clinically significant QTc prolongation (QTc >450 ms in males or >470 ms in females);
Ventricular tachycardia;
Single group
venetoclax, chidamide, and chiglitazar sodium (VCC)
DrugParticipants will receive oral chidamide 30 mg twice weekly for 2 weeks, venetoclax 200 mg once daily for 2 weeks, and chiglitazar sodium 48 mg once daily on Days 1-28 of each 28-day cycle. At least two cycles will be administered. Dose modifications are permitted according to clinical condition, laboratory findings, adverse events, and venetoclax plasma concentrations.
Composite Complete Remission Rate (CR + CRi)
The proportion of participants who achieve complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) following VCC treatment. Treatment response will be assessed according to the response criteria specified in the study protocol.
1-Year Progression-Free Survival (PFS)
The proportion of participants who are alive without disease progression at 1 year after initiation of VCC treatment. Progression-free survival is defined as the time from initiation of study treatment to disease progression or death from any cause, whichever occurs first.
1-Year Overall Survival (OS)
The proportion of participants who are alive at 1 year after initiation of VCC treatment. Overall survival is defined as the time from initiation of study treatment to death from any cause.
Change in Health-Related Quality of Life Assessed by EQ-5D-5L
Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Changes in patient-reported health status during treatment will be evaluated relative to baseline.
Incidence of Adverse Events
The incidence and severity of adverse events occurring during study treatment will be assessed based on clinical symptoms, physical examinations, vital signs, laboratory findings, and other clinically relevant safety parameters. Adverse events will be graded according to the toxicity grading criteria specified in the study protocol.
Click on the lead sponsor to view all of their trials.
